Havn Life Sciences, a biotechnology company, completed the acquisition of HAVN Research, a biotechnology company. Financial terms were not disclosed. Following completion of the acquisition, the company has 66.7m common shares in the capital of the company issued and outstanding. The common shares will be listed and posted on the Canadian Securities Exchange, and are anticipated to commence trading at market open on September 8, 2020 under the stock symbol “HAVN”.